PMID- 34476565
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 238
IP  - 12
DP  - 2021 Dec
TI  - Differences in the incidence of lurasidone adverse events between depressive 
      disorders and schizophrenia in double-blind, randomized, placebo-controlled 
      trials: a meta-analysis.
PG  - 3585-3593
LID - 10.1007/s00213-021-05975-9 [doi]
AB  - RATIONALE: We conducted a meta-analysis of double-blind, randomized 
      placebo-controlled trials of lurasidone (LUR) to examine the difference in the 
      risk ratios (RRs) for adverse events (AEs) between depressive disorders (bipolar 
      depression and major depressive disorders) and schizophrenia. OBJECTIVES: Three 
      trials for depressive disorders (n = 1,239) were used for flexible-dose LUR 20-60 
      (LUR20-60) and/or 80-120 (LUR80-120) mg/day. Nine schizophrenia trials 
      (n = 2,684) were used for fixed-dose LUR. The RRs of LUR20-60 and LUR80-120 for 
      depressive disorders were compared with those of LUR 40 (LUR40) and LUR 80 
      (LUR80) mg/day for schizophrenia, respectively, to match LUR dose. RESULTS: 
      LUR20-60 caused a higher incidence of akathisia (RR = 2.28; p = 0.003) and weight 
      gain (RR = 4.11; p = 0.05) than placebo in patients with depressive disorders, 
      and LUR40 caused a higher incidence of akathisia (RR = 2.39; p = 0.0001), 
      extrapyramidal symptoms (RR = 1.88; p = 0.02), anticholinergic drug use 
      (RR = 1.58; p = 0.005), somnolence (RR = 2.19; p = 0.002), and dizziness 
      (RR = 2.06; p = 0.05) than placebo in patients with schizophrenia. However, no 
      significant differences in the RRs for all outcomes were found between depressive 
      disorders and schizophrenia. LUR80-120 caused a higher incidence of akathisia 
      (RR = 3.90; p < 0.0001), extrapyramidal symptoms (RR = 2.26; p = 0.04), 
      anticholinergic use (RR = 4.70; p < 0.0001), and nausea (RR = 2.15; p = 0.001) 
      than placebo in patients with depressive disorders. LUR80 caused a higher 
      incidence of akathisia (RR = 2.99; p < 0.0001), extrapyramidal symptoms 
      (RR = 2.55; p = 0.01), anticholinergic use (RR = 1.86; p = 0.01), somnolence 
      (RR = 2.46; p = 0.001), and nausea (RR = 1.64; p = 0.04) than placebo in patients 
      with schizophrenia. Depressive disorders had a higher RR for anticholinergic use 
      than schizophrenia (p = 0.04). CONCLUSIONS: The incidence of AEs did not differ 
      between schizophrenia and depressive disorders.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Kishi, Taro
AU  - Kishi T
AUID- ORCID: 0000-0002-9237-2236
AD  - Department of Psychiatry, Fujita Health University School of Medicine, 1-98 
      Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. 
      tarok@fujita-hu.ac.jp.
FAU - Nakamura, Hiroshi
AU  - Nakamura H
AD  - Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Chuo-ku, Tokyo, Japan.
FAU - Iwata, Nakao
AU  - Iwata N
AD  - Department of Psychiatry, Fujita Health University School of Medicine, 1-98 
      Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210902
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antipsychotic Agents)
RN  - O0P4I5851I (Lurasidone Hydrochloride)
SB  - IM
MH  - *Antipsychotic Agents/adverse effects
MH  - *Depressive Disorder, Major/drug therapy
MH  - Humans
MH  - Incidence
MH  - Lurasidone Hydrochloride/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - *Schizophrenia/drug therapy
OTO - NOTNLM
OT  - Adverse events
OT  - Depressive disorders
OT  - Lurasidone
OT  - Schizophrenia
OT  - Systematic review and meta-analysis
EDAT- 2021/09/04 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/09/03 07:00
PHST- 2021/04/20 00:00 [received]
PHST- 2021/08/25 00:00 [accepted]
PHST- 2021/09/04 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/09/03 07:00 [entrez]
AID - 10.1007/s00213-021-05975-9 [pii]
AID - 10.1007/s00213-021-05975-9 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2021 Dec;238(12):3585-3593. doi: 
      10.1007/s00213-021-05975-9. Epub 2021 Sep 2.